Similar articles

• The current management of carcinoma of the prostate.

  Rodriguez R, Carter HB. Rodriguez R, et al. Adv Surg. 1999;33:181-97. Adv Surg. 1999. PMID: 10572567 Review. No abstract available.
• What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.

  Teeter AE, Bañez LL, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ; SEARCH Database Group. Teeter AE, et al. J Urol. 2008 Nov;180(5):1980-4; discussion 1985. doi: 10.1016/j.juro.2008.07.031. Epub 2008 Sep 17. J Urol. 2008. PMID: 18801519 Free PMC article.
• The importance of surgical margins in prostate cancer.

  Sooriakumaran P, Dev HS, Skarecky D, Ahlering T. Sooriakumaran P, et al. J Surg Oncol. 2016 Mar;113(3):310-5. doi: 10.1002/jso.24109. Epub 2016 Mar 23. J Surg Oncol. 2016. PMID: 27004601 Review.
• Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?

  Lynch MJ. Lynch MJ. J Urol. 2005 Sep;174(3):1155; author reply 1155-6. doi: 10.1016/s0022-5347(01)68555-0. J Urol. 2005. PMID: 16094096 No abstract available.
• [Prostate cancer screening with a new marker based on circulating blood macrophages?].

  Herwig R, Djavan B, Kramer G, El-Taieb MA, Kühhas F, Leers M, Marberger M. Herwig R, et al. Urologe A. 2007 Sep;46(9):1066-70. doi: 10.1007/s00120-007-1421-7. Urologe A. 2007. PMID: 17622505 German. No abstract available.